Actinomycosis

Summary

Actinomycosis (MONDO:0005631) is a disease and 1 clinical trial. A subtype of commensal bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	actinomycosis
Mondo ID	MONDO:0005631
EFO	EFO:0007128
MeSH	D000196
Orphanet	457095
DOID	DOID:8478
ICD-10-CM	A42
ICD-11	1697630330
NCIT	C34350
UMLS	C0001261
MedGen	1733
GARD	0005728
Is cancer (heuristic)	no

Also known as: Actinomyces infection · Actinomyces israeli · Actinomycetes · anaerobic Actinomyces infection · canaliculitis · infections, Actinomyces · Keratoactinomycosis

Disease family

This is a subtype of commensal bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › actinomycosis

Related subtypes (5): toxic shock syndrome, chlamydia trachomatis infectious disease, gas gangrene, Lemierre syndrome, staphylococcal scalded skin syndrome

Subtypes (3): chronic canaliculitis, cervicofacial actinomycosis, aerobic Actinomyces infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06523998	Not specified	COMPLETED	A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.